Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

progyny inc - PGNY

PGNY

Close Chg Chg %
25.84 0.09 0.35%

Open Market

25.93

+0.09 (0.35%)

Volume: 141.80K

Last Updated:

Dec 31, 2025, 11:51 AM EDT

Trade Now

Company Overview: progyny inc - PGNY

PGNY Key Data

Open

$25.80

 Day Range

25.71 - 26.13

52 Week Range

16.95 - 27.76

 Market Cap

$2.21B

Shares Outstanding

86.21M

 Public Float

72.27M

Beta

0.97

 Rev. Per Employee

N/A

P/E Ratio

40.85

 EPS

$0.66

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.39M

  

PGNY Performance

1 Week
 
 -0.70%
 
1 Month
 
 -2.84%
 
3 Months
 
 24.43%
 
1 Year
 
 48.52%
 
5 Years
 
 -39.56%
 

PGNY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About progyny inc - PGNY

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

PGNY At a Glance

Progyny, Inc.
1359 Broadway
New York, New York 10018
Phone 1-212-888-3124 Revenue 1.17B
Industry Miscellaneous Commercial Services Net Income 54.34M
Sector Commercial Services 2024 Sales Growth 7.222%
Fiscal Year-end 12 / 2025 Employees 680
View SEC Filings

PGNY Valuation

P/E Current 40.849
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 30.30
Price to Sales Ratio 1.411
Price to Book Ratio 3.487
Price to Cash Flow Ratio 9.19
Enterprise Value to EBITDA 20.357
Enterprise Value to Sales 1.232
Total Debt to Enterprise Value 0.013

PGNY Efficiency

Revenue/Employee 1,716,501.471
Income Per Employee 79,905.882
Receivables Turnover 4.96
Total Asset Turnover 1.697

PGNY Liquidity

Current Ratio 2.803
Quick Ratio 2.803
Cash Ratio 1.352

PGNY Profitability

Gross Margin 21.707
Operating Margin 5.779
Pretax Margin 7.128
Net Margin 4.655
Return on Assets 7.901
Return on Equity 11.14
Return on Total Capital 12.312
Return on Invested Capital 10.769

PGNY Capital Structure

Total Debt to Total Equity 4.566
Total Debt to Total Capital 4.367
Total Debt to Total Assets 3.148
Long-Term Debt to Equity 3.889
Long-Term Debt to Total Capital 3.719
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Progyny Inc - PGNY

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
500.62M 786.91M 1.09B 1.17B
Sales Growth
+45.17% +57.19% +38.34% +7.22%
Cost of Goods Sold (COGS) incl D&A
388.49M 619.59M 849.80M 913.86M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.30M 1.60M 2.28M 3.17M
Depreciation
700.00K 1.10M 2.20M 3.10M
Amortization of Intangibles
601.00K 501.00K 81.00K 75.00K
COGS Growth
+41.37% +59.49% +37.16% +7.54%
Gross Income
112.14M 167.32M 238.80M 253.36M
Gross Income Growth
+60.06% +49.22% +42.72% +6.10%
Gross Profit Margin
+22.40% +21.26% +21.94% +21.71%
2021 2022 2023 2024 5-year trend
SG&A Expense
79.80M 143.98M 176.62M 185.91M
Research & Development
- - - -
-
Other SG&A
79.80M 143.98M 176.62M 185.91M
SGA Growth
+29.30% +80.44% +22.66% +5.26%
Other Operating Expense
- - - -
-
Unusual Expense
- - (3.90M) (7.30M)
-
EBIT after Unusual Expense
32.34M 23.34M 66.08M 74.75M
Non Operating Income/Expense
95.00K 1.10M 4.61M 9.98M
Non-Operating Interest Income
- 461.00K 814.00K 3.30M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 1.53M
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - 1.53M
-
Interest Capitalized
- - - -
-
Pretax Income
32.44M 24.44M 70.69M 83.20M
Pretax Income Growth
+273.72% -24.65% +189.23% +17.70%
Pretax Margin
+6.48% +3.11% +6.49% +7.13%
Income Tax
(33.33M) (5.92M) 8.65M 28.87M
Income Tax - Current - Domestic
(31.00K) 695.00K 4.91M 39.32M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(33.30M) (6.61M) 3.75M (10.46M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
65.77M 30.36M 62.04M 54.34M
Minority Interest Expense
- - - -
-
Net Income
65.77M 30.36M 62.04M 54.34M
Net Income Growth
+41.56% -53.84% +104.35% -12.41%
Net Margin Growth
+13.14% +3.86% +5.70% +4.66%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
65.77M 30.36M 62.04M 54.34M
Preferred Dividends
- - - -
-
Net Income Available to Common
65.77M 30.36M 62.04M 54.34M
EPS (Basic)
0.7381 0.3293 0.6529 0.594
EPS (Basic) Growth
+36.18% -55.39% +98.27% -9.02%
Basic Shares Outstanding
89.11M 92.20M 95.02M 91.48M
EPS (Diluted)
0.6553 0.3037 0.6162 0.5693
EPS (Diluted) Growth
+39.72% -53.65% +102.90% -7.61%
Diluted Shares Outstanding
100.36M 99.96M 100.67M 95.45M
EBITDA
33.64M 24.94M 64.47M 70.63M
EBITDA Growth
+228.08% -25.86% +158.46% +9.56%
EBITDA Margin
+6.72% +3.17% +5.92% +6.05%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 29.10
Number of Ratings 11 Current Quarters Estimate 0.145
FY Report Date 12 / 2025 Current Year's Estimate 0.658
Last Quarter’s Earnings 0.15 Median PE on CY Estimate N/A
Year Ago Earnings 0.57 Next Fiscal Year Estimate 0.958
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 6 10 10
Mean Estimate 0.15 0.23 0.66 0.96
High Estimates 0.18 0.26 0.69 1.18
Low Estimate 0.12 0.19 0.64 0.76
Coefficient of Variance 11.38 13.11 2.46 15.68

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 5
OVERWEIGHT 1 0 0
HOLD 4 4 5
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Progyny Inc - PGNY

Date Name Shares Transaction Value
Dec 5, 2025 Mark Livingston CHIEF FINANCIAL OFFICER 48,134 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $25.27 per share 1,216,346.18
Dec 5, 2025 Mark Livingston CHIEF FINANCIAL OFFICER 47,921 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.5 per share 1,221,985.50
Dec 5, 2025 Michael Sturmer PRESIDENT 296,210 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $25.27 per share 7,485,226.70
Apr 4, 2025 Peter Anevski CHIEF EXECUTIVE OFFICER; Director 555,518 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $22.34 per share 12,410,272.12
Apr 4, 2025 David J. Schlanger Executive Chairman; Director 224,205 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $22.34 per share 5,008,739.70
Mar 6, 2025 Peter Anevski CHIEF EXECUTIVE OFFICER; Director 174,239 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Mark Livingston CHIEF FINANCIAL OFFICER 74,359 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $22 per share 1,635,898.00
Mar 6, 2025 Mark Livingston CHIEF FINANCIAL OFFICER 49,783 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Michael Sturmer PRESIDENT 313,508 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $22 per share 6,897,176.00
Mar 6, 2025 Allison Swartz EVP, GC 85,203 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Allison Swartz EVP, GC 83,786 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $22 per share 1,843,292.00
Mar 6, 2025 Allison Swartz EVP, GC 31,115 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Progyny Inc in the News